admin – Page 4861 – Get News Story

Explore China Like Never Before with China Expedition Tours’ Private Group Tours

Guilin, China – 19 November, 2024 – For families, friends, and special interest groups seeking an unparalleled travel experience, China Expedition Tours (CET) is redefining group private tours to China. With a focus on authentic cultural immersion, personalized itineraries, and exceptional service, CET invites travelers to discover China in ways that go beyond the typical tourist trails.

Authentic Experiences That Inspire

CET’s private group China tours offer more than just sightseeing. Travelers can immerse themselves in deep, culturally rich experiences, such as participating in traditional Chinese tea ceremonies, exploring local markets, or visiting ancient villages steeped in history. These unique activities provide an insider’s view of China’s vibrant heritage.

Connect with Local Communities

Unlike conventional tours, CET emphasizes interaction with local people, fostering meaningful connections and unforgettable memories. Whether it’s learning calligraphy from a master artist or sharing a meal with a local family, CET ensures every traveler feels welcomed and engaged.

Tailored to Your Interests

CET specializes in crafting custom itineraries based on each group’s specific preferences. Whether you’re captivated by historical landmarks, natural wonders, or culinary delights, CET creates journeys designed just for you.

The CET Difference

– Exceptional Local Guides: Travel with the most experienced and compassionate guides who bring China’s stories to life.

– Family and Friends Focus: Perfect for reunions, friend getaways, or multi-generational travel.

– Worry-Free Planning: Enjoy seamless communication, hassle-free logistics, and full-service support from start to finish.

Plan Your Adventure Today

China Expedition Tours combines cultural depth, personalized service, and professional care to deliver unforgettable group travel experiences.

Get Your FREE China Travel Guide Today!

Visit www.chinaexpeditiontours.com or email info@chinaexpeditiontours.com to start planning your dream private group tour to China.

About China Expedition Tours

China Expedition Tours (CET) is a leading provider of private group tours, offering authentic and customized travel experiences across China. With a commitment to cultural immersion, local connection, and exceptional service, CET brings the beauty and richness of China to travelers worldwide.

Media Contact
Company Name: China Expedition Tours
Contact Person: Chanel Tang
Email: Send Email
Phone: +86-13978369041
Country: China
Website: https://www.chinaexpeditiontours.com/

In this Year of the Dragon, the real Santer releases Adventure Fantasy The Dragon Who Found His Wings perfect for Christmas Stocking Fillers

Lynn Santer’s The Dragon Who Found His Wings follows a courageous water dragon and a group of unlikely friends on an incredible adventure to save an entire community. Together, they face challenges that test their courage, wisdom, and the bonds that hold them together. Not just a story of adventure, the book offers profound reflections on the power of kindness, friendship, bravery, and the mysteries of life.

Lynn Santer is an internationally acclaimed film producer and best-selling author.

Her debut novel, “Sins of Life” became the #1 selling title for its publisher and was optioned by Zygi Kamasa, involved in the “Kingsman” franchise, “Olympus has Fallen”, “The Expendables 2”. Since then, she has authored or ghosted over fifty titles. Her documentary films exposing the brutal truths behind the trophy hunting industry have received international acclaim and won at film festivals worldwide.

Residing on a tranquil lake in Australia has been the inspiration for her animal adventure novels “Swan Song” and “The Dragon Who Found His Wings”. “Swan Song” went straight to #1 on Kindle in Australia, and was awarded by the coveted Readers Favorite Award and Golden Wizard Award for Book Excellence UK. Both books are being looked at for animated musical feature adaptation. This one-on-one interview shares Lynn’s background and experience writing The Dragon Who Found His Wings.

Tell us about The Dragon Who Found His Wings.

“The Dragon Who Found His Wings” is an incredible adventure story that addresses very real-world issues.

The sequel to “Swan Song,” the book centers around Swimmer, the water dragon, who receives a mysterious message from an ancient tree, sending him on a perilous quest to save an entire wildlife community from certain doom.

Set in a subtropical paradise under siege from climate change and deforestation, Swimmer must challenge his beliefs and connect with his past to save the future. He unwillingly leaves his brave pregnant mate behind to face the evil dragon king, while he searches for the elusive Koolewong, the only creature who can stop their life-sustaining water supply from being poisoned.

Accompanied by Lord Quacksalot, a wise-cracking old duck, Swimmer must learn to have faith in himself in order to save his wildlife community.

What inspired you to write The Dragon Who Found His Wings?

I have lived on a 17-hectare lake in the subtropical paradise of the Gold Coast of Australia for 25 years. In this wildlife haven, I have created a sanctuary for all manner of creatures. When I started blogging about their trials and triumphs, loves and losses, personalities and petulance, I gathered a global following imploring me to write books about these characters. My first book, “Swan Song” was an anthropomorphic novel based on real events that brought to life new, colorful characters. It became an instant bestseller, loved by readers aged 8-88, and has been critically acclaimed around the world, with many likening it to “The Lion King” with black swans, “Wind in the Willows” and “Watership Down.”

Then, when my beloved wild water dragon died suddenly of a parasite infection, I was devastated. Determined to honor his memory, especially in this YEAR OF THE DRAGON, I wrote “The Dragon Who Found His Wings” which reprised some of “Swan Song’s” most loved characters as a tribute to him.

Writing the book was an incredible experience as the settings, solutions to problems, and characterizations flowed out of me as if coming from some other worldly place. The book features a completely fictional adventure using ancient knowledge to solve very real present-day issues.

How did your background and experience influence your writing?

My fascination with protecting the environment, and more specifically, endangered species, began as a child watching my father’s home-made, David Attenborough style documentaries of his visits to Africa. From there, my fascination became a love and then a passion to conserve these precious lives, not just for future generations but for the future health and biodiversity of our planet, and because they have a right to live in dignity, security and freedom.

As an adult, I organized a high-profile fundraiser in the Gold Coast’s Jupiters Casino with Hollywood legend, Tippi Hedren. I also visited Africa many times, worked hands-on with cheetah in the AfriCat Foundation, piloted a 12 seater Cessna caravan over the Kruger National Park and tracked wild predators on foot with only an indigenous guard and tracker accompanying me. I have also been made an Honorary Life Member of The AfriCat Foundation.

Ultimately, it was the confluence of my personal and professional experiences that led me to write this book.

What is one message you would like readers to remember?

I am deeply passionate about the protection, preservation and conservation of wildlife habitats.

The sad truth is that so many of our wildlife are injured or killed by thoughtlessly discarded litter, our waterways polluted by human waste, and wildlife habitats threatened by mankind’s pursuit of development dollars.

Through this story, my hope is to raise awareness about these issues and inspire others to take action to support the preservation of wildlife habitats. The book is designed to change the way we see our world with a cavalcade of charismatic and colorful characters.

I have also included some organizations to contact to learn more and get involved in the epilogue of the book.

Purchasing the Book

“The Dragon Who Found His Wings” has received positive reviews from well-known literary organizations, authors, and reviewers around the world. Priscilla Presley writes, “BRAVO Lynn…kudos on this book.” In addition, editor Lynne G Walker writes, “The Dragon Who Found His Wings is the best book I’ve read in ages… reading it, I had the image of a Disney-type film in my head…compelling characters, an absorbing story, great dialogue, conflict, arcing, and a satisfying ending…I loved it!”

The Dragon Who Found His Wings is available for sale on Amazon. Readers are encouraged to purchase their copy today: https://www.amazon.com/Dragon-Found-Mermaid-Waters-Stories-ebook/dp/B0DJVJ4H88/

You can also watch the official book trailer here: https://youtu.be/ScIVUReeUxw

To connect with Lynn and learn more about her work, visit: www.LynnSanter.com and www.SwanLakePress.com. You can also find her on Facebook.

Media Contact
Company Name: Author News Network
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: authornewsnetwork.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: In this Year of the Dragon, the real Santer releases Adventure Fantasy The Dragon Who Found His Wings perfect for Christmas Stocking Fillers

Familial Hypercholesterolemia Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Verve Therapeutics, LIB Therapeutics, Arrowhead Pharma, Regeneron Pharma

The Key Familial Hypercholesterolemia Companies in the market include – Verve Therapeutics, LIB Therapeutics, Arrowhead Pharmaceuticals, Regeneron Pharmaceuticals, Amgen, and others.

DelveInsight’s “Familial Hypercholesterolemia Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Familial Hypercholesterolemia, historical and forecasted epidemiology as well as the Familial Hypercholesterolemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Familial Hypercholesterolemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Familial Hypercholesterolemia Market Forecast

Some of the key facts of the Familial Hypercholesterolemia Market Report:

The Familial Hypercholesterolemia market size is anticipated to grow with a significant CAGR of 12% during the study period (2020-2034)
In July 2024, NewAmsterdam Pharma achieved a significant milestone in its Phase III clinical program, with its lead cardiovascular candidate, obicetrapib, demonstrating cholesterol-lowering efficacy in the pivotal BROOKLYN trial (NCT05425745). This trial, the first of four in the company’s portfolio, evaluates obicetrapib in adult patients with heterozygous familial hypercholesterolemia (HeFH) who have inadequately controlled LDL-C levels despite receiving the highest tolerable doses of lipid-lowering therapies.
DelveInsight’s epidemiology model estimates that in 2023, there were approximately 361 thousand diagnosed cases of Familial Hypercholesterolemia in the US. This number is expected to grow during the forecast period (2024–2034), driven by heightened awareness, expanded screening, and advancements in genetic testing.
In 2023, France reported the highest number of diagnosed prevalent cases of Familial Hypercholesterolemia among the EU4 and the UK, with around 58 thousand cases, followed by the UK with approximately 54 thousand cases, and Germany with nearly 53 thousand cases.
In the US, the highest number of diagnosed prevalent cases of Familial Hypercholesterolemia in 2023 were seen in the 50–59 years age group, with approximately 94 thousand cases, while the lowest number was observed in the 30–39 years age group, with around 27 thousand cases.
In 2023, Japan had the second-highest number of diagnosed prevalent cases of Familial Hypercholesterolemia among the 7MM, with approximately 69 thousand cases.
Key Familial Hypercholesterolemia Companies: Verve Therapeutics, LIB Therapeutics, Arrowhead Pharmaceuticals, Regeneron Pharmaceuticals, Amgen, and others
Key Familial Hypercholesterolemia Therapies: VERVE-101, Lerodalcibep, Zodasiran, EVKEEZA (evinacumab-dgnb), PRALUENT (alirocumab), REPATHA (evolocumab), and others
The Familial Hypercholesterolemia epidemiology based on mutation-specific cases analyzed that a mutation in the LDLR gene accounted for the highest diagnosed prevalent cases in the US
The Familial Hypercholesterolemia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Familial Hypercholesterolemia pipeline products will significantly revolutionize the Familial Hypercholesterolemia market dynamics.

Familial Hypercholesterolemia Overview

Familial Hypercholesterolemia is a genetic disorder characterized by high levels of low-density lipoprotein (LDL) cholesterol in the blood. It is caused by mutations in the genes responsible for regulating cholesterol levels, such as the LDL receptor gene. Individuals with FH have a higher risk of developing cardiovascular diseases, including heart attacks, at a younger age due to the accumulation of cholesterol in their arteries. FH can be inherited in an autosomal dominant pattern, meaning one copy of the mutated gene from either parent is sufficient to cause the disorder. Early diagnosis and treatment, often with cholesterol-lowering medications, are essential to manage the condition and reduce the risk of complications.

Get a Free sample for the Familial Hypercholesterolemia Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/familial-hypercholesterolemia-market-report

Familial Hypercholesterolemia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Familial Hypercholesterolemia Epidemiology Segmentation:

The Familial Hypercholesterolemia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Diagnosed Prevalent Cases of Familial Hypercholesterolemia in the 7MM
Mutation-specific Diagnosed Prevalent Cases of Familial Hypercholesterolemia in the 7MM

Download the report to understand which factors are driving Familial Hypercholesterolemia epidemiology trends @ Familial Hypercholesterolemia Epidemiology Forecast

Familial Hypercholesterolemia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Familial Hypercholesterolemia market or expected to get launched during the study period. The analysis covers Familial Hypercholesterolemia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Familial Hypercholesterolemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Familial Hypercholesterolemia Therapies and Key Companies

VERVE-101: Verve Therapeutics
Lerodalcibep: LIB Therapeutics
Zodasiran: Arrowhead Pharmaceuticals
EVKEEZA (evinacumab-dgnb): Regeneron Pharmaceuticals
PRALUENT (alirocumab): Sanofi/ Regeneron Pharmaceuticals
REPATHA (evolocumab): Amgen

Discover more about therapies set to grab major Familial Hypercholesterolemia market share @ Familial Hypercholesterolemia Treatment Landscape

Familial Hypercholesterolemia Market Strengths

The clarity in disease understanding and pathogenesis has driven the development of novel pharmacological options like PCSK9 inhibitors, ANGPTL3 inhibitors, and MTP inhibitor
Updated international diagnostic and clinical guidelines for FH and HoFH enable evidence-based therapeutic approaches and screening strategies for early identification
Advances in research have led to the discovery of novel molecules like siRNA and recombinant fusion protein that may offer novel options to lower LDL significantly

Familial Hypercholesterolemia Market Opportunities

Preclinical studies have yielded gene therapy and CRISPR-based gene editing approaches; conducting further research and clinical trials may offer curative therapy.
Current therapies do not impart sufficient cholesterol-lowering allowing pharma players to bring newer, more potent, and better LDL-C lowering therapies and prevent ASCVD in HoFH patients.
Advancements in healthcare technologies and digital health solutions can potentially enhance early detection and personalized management of HoFH.

Scope of the Familial Hypercholesterolemia Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Familial Hypercholesterolemia Companies: Verve Therapeutics, LIB Therapeutics, Arrowhead Pharmaceuticals, Regeneron Pharmaceuticals, Amgen, and others
Key Familial Hypercholesterolemia Therapies: VERVE-101, Lerodalcibep, Zodasiran, EVKEEZA (evinacumab-dgnb), PRALUENT (alirocumab), REPATHA (evolocumab), and others
Familial Hypercholesterolemia Therapeutic Assessment: Familial Hypercholesterolemia current marketed and Familial Hypercholesterolemia emerging therapies
Familial Hypercholesterolemia Market Dynamics: Familial Hypercholesterolemia market drivers and Familial Hypercholesterolemia market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Familial Hypercholesterolemia Unmet Needs, KOL’s views, Analyst’s views, Familial Hypercholesterolemia Market Access and Reimbursement

To know more about Familial Hypercholesterolemia companies working in the treatment market, visit @ Familial Hypercholesterolemia Clinical Trials and Treatments

Table of Contents

1. Familial Hypercholesterolemia Market Report Introduction

2. Executive Summary for Familial Hypercholesterolemia

3. SWOT analysis of Familial Hypercholesterolemia

4. Familial Hypercholesterolemia Patient Share (%) Overview at a Glance

5. Familial Hypercholesterolemia Market Overview at a Glance

6. Familial Hypercholesterolemia Disease Background and Overview

7. Familial Hypercholesterolemia Epidemiology and Patient Population

8. Country-Specific Patient Population of Familial Hypercholesterolemia

9. Familial Hypercholesterolemia Current Treatment and Medical Practices

10. Familial Hypercholesterolemia Unmet Needs

11. Familial Hypercholesterolemia Emerging Therapies

12. Familial Hypercholesterolemia Market Outlook

13. Country-Wise Familial Hypercholesterolemia Market Analysis (2020–2034)

14. Familial Hypercholesterolemia Market Access and Reimbursement of Therapies

15. Familial Hypercholesterolemia Market Drivers

16. Familial Hypercholesterolemia Market Barriers

17. Familial Hypercholesterolemia Appendix

18. Familial Hypercholesterolemia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Familial Hypercholesterolemia Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Verve Therapeutics, LIB Therapeutics, Arrowhead Pharma, Regeneron Pharma

Familial Chylomicronemia Syndrome Market Expected to Experience Major Growth by 2034, According to DelveInsight | Ionis Pharma, Novartis, Akcea Therapeutics, Arrowhead Pharma, Visirna Therapeutics

The Key Familial Chylomicronemia Syndrome Companies in the market include – Arrowhead Pharma, Visirna Therapeutics HK Limited, Ionis Pharmac, Novartis, Akcea Therapeutics, and others .

DelveInsight’s “Familial Chylomicronemia Syndrome Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Familial Chylomicronemia Syndrome, historical and forecasted epidemiology as well as the Familial Chylomicronemia Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Familial Chylomicronemia Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Familial Chylomicronemia Syndrome Market Forecast

Some of the key facts of the Familial Chylomicronemia Syndrome Market Report:

The Familial Chylomicronemia Syndrome market size was valued approximately ~USD 15 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In Noevmber 2024, Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational therapy, plozasiran, aimed at treating familial chylomicronemia syndrome (FCS). FCS is a severe and rare genetic condition that currently lacks FDA-approved treatments. The company also plans to file for regulatory approval of plozasiran with other authorities in 2025.
In April 2024, Ionis Pharmaceuticals is seeking regulatory approval for its lead candidate, olezarsen, following its success in achieving the primary endpoint in a pivotal trial for adults with familial chylomicronemia syndrome (FCS). The Phase III Balance trial, a global, multicenter, randomized, double-blind, placebo-controlled study (NCT04568434), included 66 participants aged 18 and older with confirmed FCS. Patients received olezarsen at doses of 80mg or 50mg, or a placebo, administered once every four weeks over a 53-week period.
DelveInsight’s estimates indicate that the US accounted for 65% of the diagnosed prevalent FCS cases in 2022. The diagnosed prevalence of Familial Chylomicronemia Syndrome is projected to increase during the forecast period (2023–2034).
In 2022, the EU4 and the UK together represented approximately 23% of the diagnosed prevalent cases of Familial Chylomicronemia Syndrome (FCS) across the seven major markets (7MM).
In 2022, Germany had the highest diagnosed prevalent population of FCS among the EU4 and the UK, with nearly 135 cases, followed by France and the UK. Conversely, Spain had the lowest diagnosed prevalent population of FCS within this group.
In Japan, there were approximately 4,886k diagnosed prevalent cases of Familial Chylomicronemia Syndrome in 2022. The number of cases is expected to grow at a significant compound annual growth rate (CAGR).
Key Familial Chylomicronemia Syndrome Companies: Arrowhead Pharma, Visirna Therapeutics HK Limited, Ionis Pharmac, Novartis, Akcea Therapeutics, and others
Key Familial Chylomicronemia Syndrome Therapies: ARO-APOC3, VSA001 injection, Olezarsen, LCQ908, AKCEA-ANGPTL3-LRx, Volanesorsen, Plozasiran, and others
The Familial Chylomicronemia Syndrome market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Familial Chylomicronemia Syndrome pipeline products will significantly revolutionize the Familial Chylomicronemia Syndrome market dynamics.

Familial Chylomicronemia Syndrome Overview

Familial Chylomicronemia Syndrome (FCS) is a rare genetic disorder characterized by the body’s inability to properly break down fats, leading to extremely high levels of triglycerides in the blood. This condition results from a deficiency or dysfunction of lipoprotein lipase (LPL), an enzyme crucial for the metabolism of chylomicrons, which are lipoproteins that transport dietary fats in the blood.

Get a Free sample for the Familial Chylomicronemia Syndrome Market Report:

https://www.delveinsight.com/report-store/familial-chylomicronemia-syndrome-market

Familial Chylomicronemia Syndrome Epidemiology

Familial Chylomicronemia Syndrome Epidemiology Segmentation:

The Familial Chylomicronemia Syndrome market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Familial Chylomicronemia Syndrome
Prevalent Cases of Familial Chylomicronemia Syndrome by severity
Gender-specific Prevalence of Familial Chylomicronemia Syndrome
Diagnosed Cases of Episodic and Chronic Familial Chylomicronemia Syndrome

Download the report to understand which factors are driving Familial Chylomicronemia Syndrome epidemiology trends @ Familial Chylomicronemia Syndrome Epidemiology Forecast

Familial Chylomicronemia Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Familial Chylomicronemia Syndrome market or expected to get launched during the study period. The analysis covers Familial Chylomicronemia Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Familial Chylomicronemia Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Familial Chylomicronemia Syndrome Therapies and Key Companies

ARO-APOC3: Arrowhead Pharma
VSA001 injection: Visirna Therapeutics HK Limited
Olezarsen: Ionis Pharmac
LCQ908: Novartis
AKCEA-ANGPTL3-LRx: Akcea Therapeutics
Volanesorsen: Akcea Therapeutics
Plozasiran: Arrowhead Pharmaceuticals

Discover more about therapies set to grab major Familial Chylomicronemia Syndrome market share @ Familial Chylomicronemia Syndrome Treatment Market

Scope of the Familial Chylomicronemia Syndrome Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Familial Chylomicronemia Syndrome Companies: Arrowhead Pharma, Visirna Therapeutics HK Limited, Ionis Pharmac, Novartis, Akcea Therapeutics, and others
Key Familial Chylomicronemia Syndrome Therapies: ARO-APOC3, VSA001 injection, Olezarsen, LCQ908, AKCEA-ANGPTL3-LRx, Volanesorsen, Plozasiran, and others
Familial Chylomicronemia Syndrome Therapeutic Assessment: Familial Chylomicronemia Syndrome current marketed and Familial Chylomicronemia Syndrome emerging therapies
Familial Chylomicronemia Syndrome Market Dynamics: Familial Chylomicronemia Syndrome market drivers and Familial Chylomicronemia Syndrome market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Familial Chylomicronemia Syndrome Unmet Needs, KOL’s views, Analyst’s views, Familial Chylomicronemia Syndrome Market Access and Reimbursement

To know more about Familial Chylomicronemia Syndrome companies working in the treatment market, visit @ Familial Chylomicronemia Syndrome Clinical Trials and Treatment

Table of Contents

1. Familial Chylomicronemia Syndrome Market Report Introduction

2. Executive Summary for Familial Chylomicronemia Syndrome

3. SWOT analysis of Familial Chylomicronemia Syndrome

4. Familial Chylomicronemia Syndrome Patient Share (%) Overview at a Glance

5. Familial Chylomicronemia Syndrome Market Overview at a Glance

6. Familial Chylomicronemia Syndrome Disease Background and Overview

7. Familial Chylomicronemia Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Familial Chylomicronemia Syndrome

9. Familial Chylomicronemia Syndrome Current Treatment and Medical Practices

10. Familial Chylomicronemia Syndrome Unmet Needs

11. Familial Chylomicronemia Syndrome Emerging Therapies

12. Familial Chylomicronemia Syndrome Market Outlook

13. Country-Wise Familial Chylomicronemia Syndrome Market Analysis (2020–2034)

14. Familial Chylomicronemia Syndrome Market Access and Reimbursement of Therapies

15. Familial Chylomicronemia Syndrome Market Drivers

16. Familial Chylomicronemia Syndrome Market Barriers

17. Familial Chylomicronemia Syndrome Appendix

18. Familial Chylomicronemia Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Familial Chylomicronemia Syndrome Market Expected to Experience Major Growth by 2034, According to DelveInsight | Ionis Pharma, Novartis, Akcea Therapeutics, Arrowhead Pharma, Visirna Therapeutics

Facioscapulohumeral Muscular Dystrophy Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Fulcrum Therapeutics, aTyr Pharma, Fulcrum Therapeutics, Hoffmann-La Roche

The Key Facioscapulohumeral Muscular Dystrophy Companies in the market include – Fulcrum Therapeutics, aTyr Pharma, Fulcrum Therapeutics, Hoffmann-La Roche, Pfizer, Avidity Biosciences, Inc, and others.

DelveInsight’s “Facioscapulohumeral Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Facioscapulohumeral Muscular Dystrophy, historical and forecasted epidemiology as well as the Facioscapulohumeral Muscular Dystrophy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Facioscapulohumeral Muscular Dystrophy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Facioscapulohumeral Muscular Dystrophy Market Forecast

Some of the key facts of the Facioscapulohumeral Muscular Dystrophy Market Report:

The Facioscapulohumeral Muscular Dystrophy market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
In July 2024, The University of Kansas (KU) Medical Center in the US has shared initial findings from the Phase I/II trial of Avidity Biosciences’ drug, del-brax (delpacibart braxlosiran), aimed at treating facioscapulohumeral muscular dystrophy (FSHD). As the trial’s study site, KU Medical Center reported early results suggesting that del-brax may substantially reduce the expression of the DUX4 gene.
In 2023, the total prevalent cases of FSHD in the 7MM were approximately 79,000, with an expected increase by 2034.
In 2023, the United States accounted for roughly 40% of the total cases in the 7MM, with these numbers expected to rise by 2034.
According to DelveInsight’s analysts, there were approximately 6,000 cases of FSHD1 and about 300 cases of FSHD2 in Japan in 2023. These numbers are expected to decrease during the forecast period (2024–2034).
According to DelveInsight’s consultant estimates, the majority of cases among the seven major markets are attributed to FSHD1. In 2023, approximately 95% of the prevalent cases were FSHD1, as compared to FSHD2.
During the forecast period (2024–2034), pipeline candidates like losmapimod (Fulcrum Therapeutics) and RO7204239/GYM-329/RG-6237 (Hoffmann-La Roche) are anticipated to contribute to the growth of the FSHD market size.
In 2023, the total number of treated cases of FSHD in the 7MM was approximately 34,000, with an anticipated increase by 2034.
In 2023, the highest number of age-specific cases of FSHD in the 7MM was observed in patients aged 50 years and above, totaling approximately 23,000. These numbers are projected to rise in the forecast period.
Key Facioscapulohumeral Muscular Dystrophy Companies: Fulcrum Therapeutics, aTyr Pharma, Fulcrum Therapeutics, Hoffmann-La Roche, Pfizer, Avidity Biosciences, Inc, and others
Key Facioscapulohumeral Muscular Dystrophy Therapies: GYM329 (RO7204239/RG 6237), Losmapimod, ATYR1940, Losmapimod, RO7204239, MYO-029, AOC 1020, and others
The Facioscapulohumeral Muscular Dystrophy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Facioscapulohumeral Muscular Dystrophy pipeline products will significantly revolutionize the Facioscapulohumeral Muscular Dystrophy market dynamics.

Facioscapulohumeral Muscular Dystrophy Overview

Facioscapulohumeral Muscular Dystrophy (FSHD) is a genetic muscle disorder characterized by progressive muscle weakness and wasting, primarily affecting the muscles of the face (facio-), shoulder blades (scapulo-), and upper arms (humeral). It is one of the most common forms of muscular dystrophy.

Get a Free sample for the Facioscapulohumeral Muscular Dystrophy Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/facioscapulohumeral-muscular-dystrophy-market

Facioscapulohumeral Muscular Dystrophy Epidemiology

Facioscapulohumeral Muscular Dystrophy Epidemiology Segmentation:

The Facioscapulohumeral Muscular Dystrophy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Facioscapulohumeral Muscular Dystrophy
Prevalent Cases of Facioscapulohumeral Muscular Dystrophy by severity
Gender-specific Prevalence of Facioscapulohumeral Muscular Dystrophy
Diagnosed Cases of Episodic and Chronic Facioscapulohumeral Muscular Dystrophy

Download the report to understand which factors are driving Facioscapulohumeral Muscular Dystrophy epidemiology trends @ Facioscapulohumeral Muscular Dystrophy Epidemiology Forecast

Facioscapulohumeral Muscular Dystrophy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Facioscapulohumeral Muscular Dystrophy market or expected to get launched during the study period. The analysis covers Facioscapulohumeral Muscular Dystrophy market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Facioscapulohumeral Muscular Dystrophy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Facioscapulohumeral Muscular Dystrophy Therapies and Key Companies

GYM329 (RO7204239/RG 6237): Roche
Losmapimod: Fulcrum Therapeutics
ATYR1940: aTyr Pharma, Inc.
Losmapimod: Fulcrum Therapeutics
RO7204239: Hoffmann-La Roche
MYO-029: Pfizer
AOC 1020: Avidity Biosciences, Inc

Discover more about therapies set to grab major Facioscapulohumeral Muscular Dystrophy market share @ Facioscapulohumeral Muscular Dystrophy Treatment Landscape

Facioscapulohumeral Muscular Dystrophy Market Strengths

Government registries aim to facilitate and accelerate academic and clinical research in FSHD, leading to the increase in knowledge and awareness.
Currently, there are no approved therapies to treat FSHD, so there will be a high chance of reimbursement for the upcoming therapies, as the cost of the treatment will be very high, and this will be first mover advantage for the government to reimburse the drugs

Facioscapulohumeral Muscular Dystrophy Market Opportunities

Limitations in current drug therapies may lead to the need for more and more reliable treatment, which could also fuel demand growth
Developing novel therapeutics and individualized medical care based on biomarkers will present profitable commercial prospects

Scope of the Facioscapulohumeral Muscular Dystrophy Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Facioscapulohumeral Muscular Dystrophy Companies: Fulcrum Therapeutics, aTyr Pharma, Inc., Fulcrum Therapeutics, Hoffmann-La Roche, Pfizer, Avidity Biosciences, Inc, and others
Key Facioscapulohumeral Muscular Dystrophy Therapies: GYM329 (RO7204239/RG 6237), Losmapimod, ATYR1940, Losmapimod, RO7204239, MYO-029, AOC 1020, and others
Facioscapulohumeral Muscular Dystrophy Therapeutic Assessment: Facioscapulohumeral Muscular Dystrophy current marketed and Facioscapulohumeral Muscular Dystrophy emerging therapies
Facioscapulohumeral Muscular Dystrophy Market Dynamics: Facioscapulohumeral Muscular Dystrophy market drivers and Facioscapulohumeral Muscular Dystrophy market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Facioscapulohumeral Muscular Dystrophy Unmet Needs, KOL’s views, Analyst’s views, Facioscapulohumeral Muscular Dystrophy Market Access and Reimbursement

To know more about Facioscapulohumeral Muscular Dystrophy companies working in the treatment market, visit @ Facioscapulohumeral Muscular Dystrophy Clinical Trials and Treatment

Table of Contents

1. Facioscapulohumeral Muscular Dystrophy Market Report Introduction

2. Executive Summary for Facioscapulohumeral Muscular Dystrophy

3. SWOT analysis of Facioscapulohumeral Muscular Dystrophy

4. Facioscapulohumeral Muscular Dystrophy Patient Share (%) Overview at a Glance

5. Facioscapulohumeral Muscular Dystrophy Market Overview at a Glance

6. Facioscapulohumeral Muscular Dystrophy Disease Background and Overview

7. Facioscapulohumeral Muscular Dystrophy Epidemiology and Patient Population

8. Country-Specific Patient Population of Facioscapulohumeral Muscular Dystrophy

9. Facioscapulohumeral Muscular Dystrophy Current Treatment and Medical Practices

10. Facioscapulohumeral Muscular Dystrophy Unmet Needs

11. Facioscapulohumeral Muscular Dystrophy Emerging Therapies

12. Facioscapulohumeral Muscular Dystrophy Market Outlook

13. Country-Wise Facioscapulohumeral Muscular Dystrophy Market Analysis (2020–2034)

14. Facioscapulohumeral Muscular Dystrophy Market Access and Reimbursement of Therapies

15. Facioscapulohumeral Muscular Dystrophy Market Drivers

16. Facioscapulohumeral Muscular Dystrophy Market Barriers

17. Facioscapulohumeral Muscular Dystrophy Appendix

18. Facioscapulohumeral Muscular Dystrophy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Facioscapulohumeral Muscular Dystrophy Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Fulcrum Therapeutics, aTyr Pharma, Fulcrum Therapeutics, Hoffmann-La Roche

Transforming Operations: Cameron Herold’s ‘The Second in Command’ Reveals the COO as a Catalyst for Change

“The Second in Command: Unleash the Power of Your COO by Cameron Herold”

“The Second in Command” is not only an exploration of the COO role but also a manual for CEOs and business leaders looking to leverage the potential of their COOs for substantial business growth.

Scottsdale, AZ – Nov 19th, 2024 – “A COO is not just an operations manager, but a visionary executor who turns strategic plans into successful realities,” writes Cameron Herold in his groundbreaking new book, “The Second in Command.” Herold, host of The Second In Command podcast and also the former COO of 1-800-GOT-JUNK? and founder of the COO Alliance, provides an insider’s look at how Chief Operating Officers can be the driving force for transformative change in any organization.

With over 25 years of experience and pivotal roles in growing multiple companies, Herold’s book is a treasure trove of insights and strategies, illustrating how a COO’s role is integral to navigating and implementing operational transformations. The book dissects the crucial attributes and skills of successful COOs, positioning them as essential change agents who collaborate closely with CEOs to achieve business objectives.

“The Second in Command” is not only an exploration of the COO role but also a manual for CEOs and business leaders looking to leverage the potential of their COOs for substantial business growth. Herold uses real-life examples, personal experiences, and interviews with top COOs to provide a comprehensive view of this often-misunderstood role.

Herold’s expertise in building high-performance cultures, operations, and growth strategies shines throughout the book, making it a must-read for business leaders aspiring to drive change and growth in their organizations.

Media Contact
Company Name: COO Alliance
Contact Person: Meridith Kuba
Email: Send Email
Phone: 480-292-1214
Address:4400 N Scottsdale Rd Ste 9-916
City: Scottsdale
State: AZ
Country: United States
Website: www.cooalliance.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Transforming Operations: Cameron Herold’s ‘The Second in Command’ Reveals the COO as a Catalyst for Change

Flash Weather AI Boosts Precision Weather Solutions for Turf and Agriculture with T3 Acquisition

Flash Weather AI has acquired T3 (Turf Threat Tracker), enhancing precision weather forecasting for turf and agriculture. This integration combines T3’s agronomy tools with Flash Weather AI’s patented algorithms, delivering real-time, site-specific insights to optimize operations and protect investments. With features like disease forecasting and advanced lightning alerts, this partnership empowers professionals to make smarter, safer decisions. Learn more: https://flashweather.ai/media

Canton, GA – November 19, 2024 – Flash Weather AI, a leader in advanced weather intelligence, proudly announces its acquisition of T3 (Turf Threat Tracker), enhancing its ability to deliver unparalleled precision in site-specific weather data for turf and agricultural management. This milestone represents a significant step forward in empowering professionals with real-time, actionable insights to optimize operations and safeguard investments.

Jason Deese, CEO of Flash Weather AI and former NOAA meteorologist, emphasizes the importance of this acquisition:

“Two of Flash Weather AI’s core principles are to create products the world has never seen and to translate complex weather data into actionable insights for businesses and consumers. Bringing T3 into the Flash family marks a great leap forward in both principles. T3 provides unique insights in golf agronomy, and combining their expertise with our AI enhances those insights as we expand into other aspects of agronomy and beyond. This is a big day for businesses that value safety and efficiency in their operations.”

Revolutionizing Weather Management for Turf and Agriculture

T3’s state-of-the-art forecasting tools, specifically tailored for turf and agricultural managers, seamlessly integrate with Flash Weather AI’s patented algorithms to offer the most precise, actionable weather data available. The platform provides up-to-48-hour updates on key metrics such as precipitation rates, soil temperature and moisture, frost formation and dissipation times, and dew severity. These and many other turf-centric forecasts enable managers to stay ahead of every weather variable impacting their operations.

Garrett Bastardi and Herb Stevens, co-founders of T3, bring over 20 years of forecasting experience in golf and business. They reflect on their journey:

“Four years ago, T3 set out to revolutionize weather-related agricultural decisions by leveraging agronomy-centric, high-resolution weather data. By joining the Flash Weather AI family, T3’s tools will reach new heights and more businesses. Flash’s use of AI to advance weather intelligence aligns perfectly with the vision T3 set at its inception. Together, we’re building the most valuable safety and efficiency tool available for decision-makers.”

Unmatched Precision and Features

The integration of T3 with Flash Weather AI offers a suite of tools designed to empower turf and agricultural professionals:

Customizable Threshold Alerts: Real-time notifications on critical metrics such as frost risk and evapotranspiration rates.
Disease Forecasting: Predictive insights to help mitigate risks of turf and crop diseases.
Growing Degree Day Tracking and Forecasting: Facilitates long-term planning and precise application timing.
Predictive Lightning Alerts: Patented technology delivering 1 to 6 hours of advanced forecast notifications.

About Flash Weather AI

Flash Weather AI is a trailblazer in weather intelligence, leveraging cutting-edge AI and proprietary meteorological algorithms to provide predictive, real-time weather insights with updates every two minutes. With clients spanning industries such as sports, construction, insurance, and now turf management, Flash Weather AI continues to revolutionize weather decision-making globally.

For more information, visit https://flashweather.ai/media/ or contact us at info@flashweather.ai

Media Contact
Company Name: Flash Weather AI
Contact Person: Darla Kirchner, CMO
Email: Send Email
Phone: 513.477.3302
Country: United States
Website: flashweather.ai

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Flash Weather AI Boosts Precision Weather Solutions for Turf and Agriculture with T3 Acquisition

MyRegistry Announces a Strategic Partnership with Lightspeed Commerce to Integrate its Gift Registry Solutions into this Popular Unified POS and Payments Platform

Innovative Integration Provides Seamless Omni-Channel Experience for Retail Clients

Fort Lee, NJ – November 19, 2024 – MyRegistry, the leading provider of universal gift registry solutions for over 1,800 retailers worldwide, is thrilled to announce a strategic partnership with Lightspeed Commerce. This new alliance introduces an integrated gift registry and gift list software solution designed specifically for Lightspeed’s diverse retail platform, offering both online and in-store integration to meet the omni-channel needs of Lightspeed’s retail customers.

The new MyRegistry gift registry software solution will be seamlessly integrated into Lightspeed’s retail platform. “Partnering with MyRegistry marks an exciting step forward for Lightspeed as we continue to enhance the omni-channel experience for our retail customers. Integrating MyRegistry’s gift registry solution into our platform will give retailers an innovative tool to better serve their customers, whether they’re shopping online or in-store,” said JD St-Martin, President of Lightspeed Commerce. “The ability to seamlessly connect inventory with personalized gift lists offers a unique value, simplifying the gifting process for consumers while driving engagement and sales for our retail partners.”

A standout feature of the MyRegistry solution is its feature rich app, which allows customers to build and manage their gift lists for milestones like weddings and baby showers to birthdays, holidays and everyday gifting moments with ease. The MyRegistry App is designed to automatically rebrand and align with its retail partner stores, synchronizing with store inventories. This functionality enables customers to create and complete their gift lists while scanning barcodes as they browse in-store, delivering a highly personalized and convenient shopping experience.

“We are excited to partner with Lightspeed Commerce to bring this innovative gift registry solution to their extensive network of retail customers,” said Nancy Lee, President at MyRegistry. “This collaboration will not only enhance the gift registry experience for consumers but also provide significant cost savings and technological benefits to small and medium-sized retailers who might not have otherwise developed such advanced capabilities.”

The MyRegistry gift registry solution’s integration with Lightspeed’s platform represents a major advancement in the retail space, streamlining the gift registry process and empowering retailers to offer a modern, customer-centric experience.

About MyRegistry

MyRegistry is a global leader in gift registry solutions, powering over 1,800 retailers worldwide with innovative, user-friendly tools. The company’s technology enables retailers to offer personalized, seamless gift registry experiences across multiple channels, driving customer engagement and satisfaction.

Connect with us: LinkedIn, Facebook, and Instagram

About Lightspeed

Powering the businesses that are the backbone of the global economy, Lightspeed’s one-stop commerce platform helps merchants innovate to simplify, scale, and provide exceptional omnichannel customer experiences. Our cloud commerce solution transforms and unifies online and physical operations, multichannel sales, expansion to new locations, global payments, financial solutions, and connection to supplier networks.

Founded in Montréal, Canada in 2005, Lightspeed is dual-listed on the New York Stock Exchange and Toronto Stock Exchange (NYSE: LSPD) (TSX: LSPD). With teams across North America, Europe, and Asia Pacific, the company serves retail, hospitality, and golf businesses in over 100 countries.

Media Contact
Company Name: MyRegistry.com
Contact Person: Therese Sheridan
Email: Send Email
Country: United States
Website: myregistry.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: MyRegistry Announces a Strategic Partnership with Lightspeed Commerce to Integrate its Gift Registry Solutions into this Popular Unified POS and Payments Platform

Logistics Automation Market Future Growth, Global Size, Opportunities, Top Companies, Trends, Segmentation, Regional Analysis, and Forecast to 2029

“KION Group (Germany), Honeywell (US), Daifuku (Japan), IBM (US), SAP (Germany), Oracle (US), ABB (Switzerland), Samsung SDS (South Korea), Manhattan Associates (US), KUKA Group (Germany), Jungheinrich (Germany).”

Logistics Automation Market by Offering (Automated Guided Vehicles (AGVs), Autonomous Mobile Robots (AMRs), Automated Storage & Retrieval Systems, Conveyors, Warehouse Management Systems), Technology (RPA, Big Data, Blockchain) – Global Forecast to 2029

The global logistics automation market is projected to grow at a compound annual growth rate (CAGR) of 8.4%, increasing from an estimated USD 35.14 billion in 2024 to USD 52.53 billion by 2029. This growth is primarily driven by the adoption of smart warehousing systems enabled by IoT, the use of AI for data analysis to optimize supply chain operations and improve decision-making efficiency, and advancements in cold chain logistics that enhance the efficiency of temperature-sensitive deliveries.

Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=83657139

By software deployment mode, cloud is expected to grow at the highest CAGR during forecast period.

By deployment mode, cloud segment is expected to grow at highest CAGR during forecast period. Cloud-based solutions provide flexibility, scalability, and cost-effective management of the complex global supply chain that the logistics companies need to manage. The advantage of such a solution is that it has access to real-time data, which, in turn, optimizes routes, inventory management, and other fleet at different locations without requiring huge infrastructure on the on-premises network. Cloud platforms also facilitate easier integration with other digital tools such as IoT, AI, and machine learning, which otherwise helps in the smooth operation process and enhances decision-making capability. Cloud deployment also allows for easier updates and maintenance. This reduces downtime as well as overheads from IT teams. Increasing demand for remote operations and the need for more agile and scalable logistics systems is a strong driver of the continued dominance of the cloud segment in logistics automation software.

By automation software, transport system management segment is projected to grow at the highest CAGR during the forecast period.

Transportation Management Systems (TMS) are projected to grow at the highest CAGR in the logistics automation market due to increasing demand for real-time tracking, route optimization, and efficient fleet management. Companies are adopting TMS because of the rise in online shopping, the interconnected nature of supply chains worldwide, and the need to reduce operational costs. The integration of AI, IoT, and cloud technology in transportation management systems results in faster deliveries and better resource utilization. The growing emphasis on reducing carbon footprints and fuel usage is driving the implementation of transportation management systems for automating logistics, ultimately enhancing sustainability.

Asia Pacific is expected to grow at the highest CAGR during the forecast period.

Logistics automation is most likely going to be the largest market area in the Asia Pacific region, driven by rapid industrialization, rising volumes of e-commerce, and increased adoption of advanced technologies in supply chains. Major countries like China, Japan, India, and South Korea are also leading in the implementation of automation solutions to meet the ever-growing demand for faster and more efficient logistics operations. The region has a large consumer base, and the emergence of e-retailers has rapidly increased demand for streamlined logistics processes such as automated warehouses, autonomous vehicles, and AI-based inventory management systems. In addition, smart manufacturing and the effort to digitalize started by the government, mainly in China and India, are accelerating the adoption of logistics automation technologies. Asia Pacific’s strong infrastructure development and thrust towards innovation along with investments in automation technologies put this region at the commanding lead in the global logistics automation market.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=83657139

Unique Features in the Logistics Automation Market

Logistics automation heavily relies on IoT-enabled smart warehousing systems that offer real-time monitoring of inventory, equipment, and operations. These systems improve visibility and control across supply chain processes, reducing errors and boosting efficiency.

Artificial intelligence (AI) plays a pivotal role in analyzing vast amounts of logistics data. By leveraging AI, businesses can optimize routing, forecast demand, and enhance operational decision-making, resulting in significant cost and time savings.

The use of advanced robotics in logistics automation, including automated guided vehicles (AGVs) and robotic picking systems, has revolutionized material handling, order fulfillment, and warehouse management. These technologies ensure faster and more accurate operations while reducing labor costs.

Cold chain logistics automation has made significant strides, with innovative solutions designed to improve the handling of temperature-sensitive goods. These advancements ensure precise temperature monitoring and control, maintaining product integrity throughout the supply chain.

Automation solutions integrate GPS, RFID, and IoT technologies to enable real-time tracking of goods. This enhanced visibility ensures better supply chain management, reduces delays, and provides customers with up-to-date shipment status.

Major Highlights of the Logistics Automation Market

The integration of IoT in smart warehousing systems has revolutionized inventory and equipment management. These systems offer real-time monitoring and data-driven insights, optimizing warehouse operations and reducing operational inefficiencies.

AI is a key driver in logistics automation, enabling advanced data analytics to optimize routing, enhance supply chain decision-making, and predict demand. The application of AI has significantly improved operational efficiency and reduced costs across the sector.

The market has witnessed widespread adoption of robotics, including automated guided vehicles (AGVs) and robotic picking systems, to streamline material handling and order fulfillment. These technologies ensure speed, precision, and reduced reliance on manual labor.

Cold chain logistics is a growing area of focus, with automation solutions enhancing the efficiency and reliability of temperature-controlled supply chains. These innovations ensure the safe and timely delivery of temperature-sensitive products, including food and pharmaceuticals.

Automation solutions that incorporate GPS, RFID, and IoT technologies provide real-time tracking and visibility of goods across the supply chain. This capability improves transparency, reduces delays, and enhances customer satisfaction.

Autonomous vehicles and drones are emerging as transformative technologies in last-mile delivery. Their adoption is driving faster deliveries, cost savings, and sustainable logistics solutions for urban and rural areas alike.

Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=83657139

Top Companies in the Logistics Automation Market

Some leading players in the Logistics automation market include KION Group (Germany), Honeywell (US), Daifuku (Japan), IBM (US), SAP (Germany), Oracle (US), ABB (Switzerland), Samsung SDS (South Korea), Manhattan Associates (US), KUKA Group (Germany) and Jungheinrich (Germany). These players have successfully leveraged collaborative partnerships with technological vendors and tech organizations to foster innovation and drive new developments. Their significant investment in research and development enables them to explore advanced technology and enhance automation capabilities, solidifying their competitive edge and boosting market positioning.

HONEYWELL

Honeywell has established itself as one of the leaders in the logistics automation market by offering advanced warehouse solutions that address the complexities of modern distribution and fulfillment operations. Their systems enhance efficiency and adaptability, enabling businesses to manage increased SKU diversity, meet stringent service level agreements, and tackle labor shortages effectively. By integrating cutting-edge technologies such as robotics, AI, and data analytics, Honeywell Intelligrated not only optimizes operational performance but also future-proofs organizations against evolving market demands. Their commitment to innovation and customer-centric solutions has solidified their competitive advantage in the rapidly changing landscape of logistics automation.

ABB

ABB has positioned itself as one of the key player in the logistics automation market by leveraging its extensive expertise in electrification, robotics, and digitalization. The company focuses on creating integrated solutions that enhance productivity and efficiency in supply chains, addressing challenges like labor shortages and increasing demand for faster delivery. By combining advanced technologies such as artificial intelligence and machine learning with their automation systems, ABB enables businesses to streamline operations and reduce costs. Their commitment to innovation and sustainability, along with strategic partnerships and acquisitions, has further solidified their competitive advantage, allowing them to adapt to the evolving needs of the logistics sector effectively.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/logistics-automation-market-83657139.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Logistics Automation Market Future Growth, Global Size, Opportunities, Top Companies, Trends, Segmentation, Regional Analysis, and Forecast to 2029

Immersive Analytics Market Size, Share, Opportunities, Top Companies, Growth, Trends, Regional Insights, Key Segments, and Forecast to 2028

“IBM (US), Microsoft (US), SAP (Germany), Google (US), TIBCO (US), HPE (US), Magic Leap (US), Accenture (Ireland), HTC (Taiwan), Meta (US), Tableau (US), Kognitiv Spark (Canada), Aventior (US), Immersion Analytics (US), BadVR (US), Virtualitics (US), Softcare Studios (Italy), JuJu Immersive (UK), ARSOME Technology (US), Varjo (Finland).”

Immersive Analytics Market by Offering (Hardware, Solutions, Services), End-use Industry (Healthcare, Construction, Automotive & Transportation, Media & Entertainment), Application, and Region – Global Forecast to 2028.

The immersive analytics market is anticipated to expand from USD 0.8 billion in 2023 to USD 6.7 billion by 2028, registering a compound annual growth rate (CAGR) of 51.7% during the forecast period. The adoption of immersive analytics solutions has surged due to the increasing accessibility and affordability of immersive technologies such as virtual reality (VR) and augmented reality (AR). This growing demand is driven by the need to process and analyze large volumes of complex data for more effective and informed decision-making.

Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=87247007

By offering, the service segment is expected to grow with the highest CAGR during the forecast period

Immersive analytics services encompass professional and managed services. These services aim to assist organizations in effectively implementing immersive data visualization and analysis technologies, providing strategic guidance, custom development, optimized visualizations, seamless user experiences, training programs, integration with existing systems, and ongoing support. Organizations can choose services based on their specific needs to leverage immersive analytics for better insights and decision-making.

By end-use industry, the healthcare segment is expected to have the largest market share during the forecast period

Digital transformation in the healthcare industry is expected to boost the adoption of immersive analytics. The innovations and technological advancements in the healthcare industry have eased the simulation of medical devices and the monitoring and diagnosis of patients. Immersive analytics solutions help healthcare and life sciences organizations efficiently manage how patient data is collected, treated, processed, and presented for the testing and simulation of new treatments, scenarios, and devices. For example, doctors can use VR headsets to visualize a patient’s anatomy and identify potential problems. Nurses can use AR glasses to see real-time data about a patient’s condition, such as their heart rate and blood pressure.

Asia Pacific is expected to have the highest growth rate during the forecast period

The Asia Pacific has witnessed an advanced and dynamic adoption of new technologies and is expected to record the highest CAGR during the forecast period. A dense population, growing per capita income, large-scale industrialization, and urbanization are a few of the major factors driving the growth of the immersive analytics market in Asia Pacific. The strong government support for innovation in the Asia Pacific region is helping to create a favorable environment for the growth of immersive analytics. This is leading to the development of new and innovative applications of immersive analytics, which positively impact businesses and society. Governments are investing in R&D for immersive analytics because they believe this technology can create jobs, boost economic growth, and improve the quality of life. Governments are helping to accelerate the development of this promising technology by providing financial support to businesses.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=87247007

Unique Features in the Immersive Analytics Market

Immersive analytics combines virtual reality (VR) and augmented reality (AR) technologies to provide interactive, data-driven experiences. These immersive technologies enable users to visualize and interact with complex datasets in three-dimensional, real-time environments, making data analysis more intuitive and engaging.

One of the standout features of immersive analytics is its ability to present complex data in highly visual formats. Users can interact with dynamic, 3D visualizations, making it easier to identify trends, patterns, and outliers in large datasets. This enhances the user’s understanding of data, leading to more informed decision-making.

Immersive analytics allows users to explore data in real-time and interact with it in an intuitive way. Unlike traditional static data visualizations, users can manipulate data, zoom in on details, and change variables on the fly, enabling a deeper, more immediate understanding of the information being analyzed.

Immersive analytics promotes collaborative decision-making by enabling teams to interact with shared virtual spaces. VR and AR technologies allow remote team members to participate in real-time data discussions and visualizations, enhancing collaboration and reducing the need for physical presence.

Immersive analytics can support advanced simulation capabilities, allowing users to create and test different scenarios. This feature is particularly valuable for sectors like finance, healthcare, and manufacturing, where users can simulate potential outcomes and assess risks before making critical decisions.

Major Highlights of the Immersive Analytics Market

The widespread adoption of virtual reality (VR) and augmented reality (AR) technologies is a key driver of the immersive analytics market. These immersive technologies make it easier for businesses to visualize complex data and gain insights in a more interactive, engaging, and intuitive manner.

Immersive analytics enables advanced data visualization by presenting information in 3D, interactive environments. This allows users to explore and manipulate complex datasets more effectively, improving data understanding and decision-making capabilities.

Unlike traditional data analysis methods, immersive analytics allows real-time interaction with data. Users can adjust variables, zoom in on specific data points, and visualize different outcomes on the spot, facilitating more dynamic and responsive decision-making.

The applications of immersive analytics are broad, spanning various industries, including healthcare, finance, manufacturing, and logistics. The ability to visualize and simulate complex processes makes it an invaluable tool for industries requiring quick, data-driven decisions.

Immersive analytics enables collaborative decision-making by allowing multiple users to access shared data visualizations in virtual spaces. Teams can interact with the data together, even remotely, which enhances collaboration and facilitates better group decision-making.

Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=87247007

Top Companies in the Immersive Analytics Market

Immersive analytics is a field focused on using data to create interactive and realistic experiences for data exploration. While there aren’t established leaders like in other software areas, major tech companies like IBM, Google, and Microsoft are all investing in this space. These companies are developing tools for data visualization, VR analytics, and AR data exploration.

IBM Immersive Data is a tool that utilizes AR technology to explore and manipulate data in a 3D format, allowing users to identify patterns, relationships, and outliers more easily and quickly than traditional 2D tools. The tool also enables multiple users to work with the same dataset simultaneously, promoting collaboration and knowledge sharing. IBM Immersive Data is a significant advancement in data science and has the potential to revolutionize how data is analyzed and explored.

In September 2022, IBM unveiled Cognos 11.2.3, the latest addition to Cognos Analytics with Watson 11.2.x stream. This update introduces several significant improvements that will enable business users to extract more value from their data and navigate it with greater ease. The release includes a complete user interface redesign, new integrations, and a range of features offering exciting data exploration and analysis possibilities. Overall, this latest update represents a substantial step forward in IBM’s efforts to enhance the Cognos Analytics platform and empower users to make more informed decisions based on their data.

Another important player in the immersive analytics market is Microsoft. In 2023, Microsoft introduced the Immersive Analytics add-in for Microsoft Power BI, enabling users to generate captivating data visualizations within the Power BI platform. With this add-in, users can create interactive and immersive data visualizations that can be explored in a three-dimensional (3D) environment. By leveraging this functionality, users can better understand intricate data sets, facilitating enhanced comprehension and analysis.

Google, founded in 1998 by Larry Page and Sergey Brin, is a leading American multinational technology company headquartered in Mountain View, California. It specializes in Internet-related services and products, which include a powerful search engine, online advertising technologies, cloud computing, software, and hardware. Google’s parent company, Alphabet Inc., oversees its extensive range of products and services. Renowned for its innovation, Google has expanded into various sectors including artificial intelligence, autonomous vehicles through its Waymo division, and consumer electronics like the Pixel phone and Google Home smart speakers. The company’s vast ecosystem of services, including Gmail, Google Maps, Google Drive, and the Android operating system, makes it a central player in the global tech industry.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Immersive Analytics Market Size, Share, Opportunities, Top Companies, Growth, Trends, Regional Insights, Key Segments, and Forecast to 2028